You just read:

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

News provided by

Boehringer Ingelheim

Jul 29, 2015, 08:00 ET